Literature DB >> 34064300

Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2.

Nikola Hudakova1, Simona Hricikova2, Amod Kulkarni2,3, Mangesh Bhide2,3, Eva Kontsekova3, Dasa Cizkova1,3.   

Abstract

Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antibodies; cytokine storm; therapy; vaccines

Year:  2021        PMID: 34064300     DOI: 10.3390/pathogens10060636

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  153 in total

1.  What do we know about India's Covaxin vaccine?

Authors:  Kamala Thiagarajan
Journal:  BMJ       Date:  2021-04-20

2.  Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia.

Authors:  Christopher Henry; Manaf Zaizafoun; Eileen Stock; Shekhar Ghamande; Alejandro C Arroliga; Heath D White
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-10-26

3.  Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling.

Authors:  Olivier Bernard; Florence Jeny; Yurdagül Uzunhan; Elisabetta Dondi; Rahma Terfous; Rabab Label; Angela Sutton; Jérôme Larghero; Valérie Vanneaux; Hilario Nunes; Emilie Boncoeur; Carole Planès; Nicolas Dard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-22       Impact factor: 5.464

4.  Re: It Is Time to Address Airborne Transmission of COVID-19.

Authors:  Zain Chagla; Susy Hota; Sarah Khan; Dominik Mertz
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

5.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

6.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.

Authors:  Ka-Tim Choy; Alvina Yin-Lam Wong; Prathanporn Kaewpreedee; Sin Fun Sia; Dongdong Chen; Kenrie Pui Yan Hui; Daniel Ka Wing Chu; Michael Chi Wai Chan; Peter Pak-Hang Cheung; Xuhui Huang; Malik Peiris; Hui-Ling Yen
Journal:  Antiviral Res       Date:  2020-04-03       Impact factor: 5.970

7.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

8.  Furin: A Potential Therapeutic Target for COVID-19.

Authors:  Canrong Wu; Mengzhu Zheng; Yueying Yang; Xiaoxia Gu; Kaiyin Yang; Mingxue Li; Yang Liu; Qingzhe Zhang; Peng Zhang; Yali Wang; Qiqi Wang; Yang Xu; Yirong Zhou; Yonghui Zhang; Lixia Chen; Hua Li
Journal:  iScience       Date:  2020-10-05

9.  Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Authors:  Hongchao Pan; Richard Peto; Ana-Maria Henao-Restrepo; Marie-Pierre Preziosi; Vasee Sathiyamoorthy; Quarraisha Abdool Karim; Marissa M Alejandria; César Hernández García; Marie-Paule Kieny; Reza Malekzadeh; Srinivas Murthy; K Srinath Reddy; Mirta Roses Periago; Pierre Abi Hanna; Florence Ader; Abdullah M Al-Bader; Almonther Alhasawi; Emma Allum; Athari Alotaibi; Carlos A Alvarez-Moreno; Sheila Appadoo; Abdullah Asiri; Pål Aukrust; Andreas Barratt-Due; Samir Bellani; Mattia Branca; Heike B C Cappel-Porter; Nery Cerrato; Ting S Chow; Najada Como; Joe Eustace; Patricia J García; Sheela Godbole; Eduardo Gotuzzo; Laimonas Griskevicius; Rasha Hamra; Mariam Hassan; Mohamed Hassany; David Hutton; Irmansyah Irmansyah; Ligita Jancoriene; Jana Kirwan; Suresh Kumar; Peter Lennon; Gustavo Lopardo; Patrick Lydon; Nicola Magrini; Teresa Maguire; Suzana Manevska; Oriol Manuel; Sibylle McGinty; Marco T Medina; María L Mesa Rubio; Maria C Miranda-Montoya; Jeremy Nel; Estevao P Nunes; Markus Perola; Antonio Portolés; Menaldi R Rasmin; Aun Raza; Helen Rees; Paula P S Reges; Chris A Rogers; Kolawole Salami; Marina I Salvadori; Narvina Sinani; Jonathan A C Sterne; Milena Stevanovikj; Evelina Tacconelli; Kari A O Tikkinen; Sven Trelle; Hala Zaid; John-Arne Røttingen; Soumya Swaminathan
Journal:  N Engl J Med       Date:  2020-12-02       Impact factor: 91.245

Review 10.  Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential.

Authors:  Maroun Khoury; Patricia R M Rocco; Donald G Phinney; Mauro Krampera; Ivan Martin; Sowmya Viswanathan; Jan A Nolta; Katarina LeBlanc; Jacques Galipeau; Daniel J Weiss
Journal:  Cytotherapy       Date:  2020-04-17       Impact factor: 5.414

View more
  1 in total

1.  Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.

Authors:  Catherine Mark; Sumit Gupta; Angela Punnett; Julia Upton; Julia Orkin; Adelle Atkinson; Lindsay Clarke; Alice Heisey; Christine McGovern; Sarah Alexander
Journal:  Pediatr Blood Cancer       Date:  2021-08-16       Impact factor: 3.838

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.